Partial
Partially Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely match the label where explicit, notably for lipid-related effects and certain dosing statements, but there are numerous substantive safety and pediatric-specific omissions and several off-label plausible claims not supported by the label. Overall, partial alignment with meaningful safety omissions.
Category Scores
Accurate Statements
Niacin plays a crucial role in cholesterol metabolism.
12.2 Pharmacodynamics; 14.1 Niacin Clinical Studies
Start with a low dose.
2 DOSAGE AND ADMINISTRATION
Niacin supplements can interact with cholesterol-lowering medications.
7 DRUG INTERACTIONS; 2 DOSAGE AND ADMINISTRATION
High doses of niacin can lead to stomach upset.
2 DOSAGE AND ADMINISTRATION
High doses of niacin can lead to nausea.
2 DOSAGE AND ADMINISTRATION
High doses of niacin can lead to diarrhea.
2 DOSAGE AND ADMINISTRATION
Niacin supplements are not recommended for children with liver disease.
5 WARNINGS AND PRECAUTIONS; 8.7 Hepatic Impairment
Unsupported Statements
Niacin is an essential nutrient.
Not stated as an essential nutrient in the FDA label; safety and efficacy focus is lipid management and pediatric safety.
Niacin plays a crucial role in energy production.
Label discusses lipid effects and NAD/NADH context but does not characterize energy production as a crucial role.
Niacin plays a crucial role in DNA repair.
Not described in mechanism or pharmacodynamics sections of the label.
Niacin plays a crucial role in DNA repair.
Duplicated; not supported by label.
Niacin has been linked to improved cognitive function in children.
Label 8.4 Pediatric Use states safety/effectiveness not established; no cognitive endpoints described.
Niacin has been linked to improved memory in children.
Label 8.4 Pediatric Use; no pediatric cognitive endpoints described.
Niacin has been linked to improved attention in children.
Label 8.4 Pediatric Use; no pediatric cognitive endpoints described.
Niacin has been shown to enhance the immune system.
Label 12.2 discusses pharmacodynamics but not enhancement of immune function.
Niacin reduces the risk of infections and diseases.
Label 12.2 discusses lipid effects, not infection risk reduction.
Niacin is essential for healthy skin and hair growth.
Label 8.4 Pediatric Use indicates safety not established; no dermatologic/hair growth claims.
Supplements can help address acne.
Not supported by label; no dermatologic efficacy claims.
Supplements can help address eczema.
Not supported by label.
Supplements can help address hair loss.
Not supported by label.
Monitor for side effects such as flushing.
Label does not explicitly instruct monitoring specific to pediatric flushing in this context.
Monitor for gastrointestinal issues.
Label mentions GI distress but not as a monitoring directive in general pediatric context.
Monitor for liver damage.
Label discusses hepatic impairment and contraindication but does not provide an explicit monitoring directive.
The recommended daily intake of niacin for children 1-3 years old is 2-3 mg.
No age-specific daily intake values are provided in the label's pediatric section.
The recommended daily intake of niacin for children 4-8 years old is 4-6 mg.
No age-specific daily intake values are provided in the label's pediatric section.
The recommended daily intake of niacin for children 9-13 years old is 8-10 mg.
No age-specific daily intake values are provided in the label's pediatric section.
Niacin supplements can interact with blood thinners.
Label's drug interactions section mentions lipid-lowering interactions; anticoagulant interactions are not specified.
Niacin supplements can interact with diabetes medications.
Label's drug interactions section does not specify antidiabetic interactions.
Niacin supplements can take several weeks to a few months to take effect.
Onset of lipid effects is discussed in pharmacodynamics, but no explicit timeframe for pediatric onset is stated.
If a child has a pre-existing medical condition, consult a healthcare professional before giving niacin supplements.
Pediatric-specific consultation guidance is not explicit in 8.4 Pediatric Use.
Niacin supplements are not recommended for children with liver disease.
This is supported by the label as a contraindication for hepatic impairment; however the statement as a separate guidance is not explicitly phrased exactly as given in the label.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Explicit pediatric adverse reaction details (flushing, pruritus, rash) and their frequency/severity.
Importance:
High
Explicit long-term hepatic safety risk at high doses, including monitoring recommendations and liver-function considerations for extended use.
Importance:
High
Pediatric dosing guidance with age-specific daily recommendations.
Importance:
High
Formal guidance on monitoring liver function or hepatic safety in at-risk populations.
Importance:
High
Clear guidance about consulting a healthcare professional before use in pediatric patients with pre-existing conditions.
Importance:
High
Explicit drug interactions with anticoagulants and antidiabetic agents in the label context.
Importance:
High
Explicit onset of action timeframe for pediatric lipid-lowering effects.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label-aligned statements exist for lipid effects and some dosing; however, there are significant safety omissions for pediatric use and long-term hepatic risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Significant pediatric safety omissions (adverse reactions in children, liver safety, age-specific dosing) and several off-label plausible claims not supported by the label.
Suggested Improvement
Update labeling to include explicit pediatric adverse reaction language (flushing, pruritus, rash), hepatic safety warnings with long-term high-dose use, age-specific dosing guidance, explicit consultations before pediatric use, and clarify drug interactions with anticoagulants and antidiabetic agents.